RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue

BACKGROUND: While standard RNA expression tests stratify patients into risk groups, RNA-Seq can guide personalized drug selection based on expressed mutations, fusion genes, and differential expression (DE) between tumor and normal tissue. However, patient-matched normal tissue may be unavailable. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Forster, Michael, Mark, Adam, Egberts, Friederike, Rosati, Elisa, Rodriguez, Elke, Stanulla, Martin, Bauerschlag, Dirk, Schem, Christian, Maass, Nicolai, Amallraja, Anu, Murphy, Karla K., Prouse, Bruce R., Sulaiman, Raed A., Young, Brandon M., Mathiak, Micaela, Hemmrich-Stanisak, Georg, Ellinghaus, David, Weidinger, Stephan, Rosenstiel, Philip, Arnold, Norbert, Leyland-Jones, Brian, Williams, Casey B., Franke, Andre, Meißner, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122351/
https://www.ncbi.nlm.nih.gov/pubmed/30190792
http://dx.doi.org/10.18632/oncotarget.25981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122351/
https://www.ncbi.nlm.nih.gov/pubmed/30190792
http://dx.doi.org/10.18632/oncotarget.25981

Ejemplares similares